The significant positive correlation between BTLA expression and other immune checkpoints including CD96 and PD1 with its ligands indicate that BTLA-inhibition in oral cancer might be promising, especially in the form of a combination immunotherapy. The gene discussed is CD96; the disease is lip and oral cavity carcinoma.